Everyone in pharma is asking what AI can do.
Everyone in pharma is asking what AI can do. Fewer are asking what it actually costs. The token bill is becoming visible, but it is only the small part. The bigger cost is often hidden in data readiness, integration, compliance review, human oversight, training, governance and the organisational redesign needed to turn a clever pilot into a useful, safe, scalable capability.
Read article